Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06927349 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. | PHASE1 | RECRUITING | 70 | — | — | Jan 11, 2023 | Dec 31, 2026 | Apr 15, 2025 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| BA1301 | EXPERIMENTAL | BA1301 is administered intravenously once every three weeks. |
| Name | Type | Description |
|---|---|---|
| BA1301 | DRUG | BA1301 is administered intravenously once every three weeks. |
Inclusion Criteria: 1. Voluntarily signed informed consent and able to follow the trial treatment protocol and visit plan; 2. Age ≥ 18 years old and ≤ 75 years old, male or female; 3. Patients with locally advanced or metastatic malignant solid tumours that cannot be surgically resected as histolog...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |